In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating treatment moved from the delay of progression to the induction of the deepest possible response. As a result of these advances, a great scientific effort has been made to redefine response monitoring, resulting in the development and validation of high-sensitivity techniques to detect minimal residual disease (MRD). In 2016, the International Myeloma Working Group (IMWG) updated MM response categories defining MRD-negative responses both in the bone marrow (assessed by next-generation flow cytometry or next-generation sequencing) and outside the bone marrow. MRD is an important factor independently predicting prognosis during MM treatment. Moreover, using novel combination therapies, MRD-negative status can be achieved in a fairly high percentage of patients. However, many questions regarding the clinical use of MRD status remain unanswered. MRD monitoring can guide treatment intensity, although well-designed clinical trials are needed to demonstrate this potential. This mini-review will focus on currently available techniques and data on MRD testing and their potential future applications.

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma

Oliva S.
Co-first
;
D'Agostino M.
Co-first
;
Boccadoro M.;Larocca A.
Last
2020-01-01

Abstract

In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating treatment moved from the delay of progression to the induction of the deepest possible response. As a result of these advances, a great scientific effort has been made to redefine response monitoring, resulting in the development and validation of high-sensitivity techniques to detect minimal residual disease (MRD). In 2016, the International Myeloma Working Group (IMWG) updated MM response categories defining MRD-negative responses both in the bone marrow (assessed by next-generation flow cytometry or next-generation sequencing) and outside the bone marrow. MRD is an important factor independently predicting prognosis during MM treatment. Moreover, using novel combination therapies, MRD-negative status can be achieved in a fairly high percentage of patients. However, many questions regarding the clinical use of MRD status remain unanswered. MRD monitoring can guide treatment intensity, although well-designed clinical trials are needed to demonstrate this potential. This mini-review will focus on currently available techniques and data on MRD testing and their potential future applications.
2020
10
1
1
10
https://www.frontiersin.org/articles/10.3389/fonc.2020.00001/full
https://doi.org/10.3389/fonc.2020.00001
http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7006453/
clinical practice; minimal residual disease (MRD); multiple myeloma (MM); next-generation flow (NGF); next-generation sequencing (NGS); PET/CT
Oliva S.; D'Agostino M.; Boccadoro M.; Larocca A.
File in questo prodotto:
File Dimensione Formato  
[Publisher Version] Oliva S et al - 2020 - Clinical application and future directions of MRD in MM - fonc-10-00001.pdf

Accesso aperto

Descrizione: [PUBLISHED Version] Oliva S, D'Agostino M, et al. Front Oncol. 2020 Jan 31;10:1. doi: 10.3389/fonc.2020.00001. PMID: 32076595; PMCID: PMC7006453. © 2020 Oliva, D’Agostino, Boccadoro and Larocca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The original article is available at the following URL: https://www.frontiersin.org/articles/10.3389/fonc.2020.00001/full | https://doi.org/10.3389/fonc.2020.00001 | http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7006453/
Tipo di file: PDF EDITORIALE
Dimensione 3.72 MB
Formato Adobe PDF
3.72 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1732734
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 20
social impact